On the evening of October 30, Proya Cosmetics Co., Ltd. (hereinafter referred to as “Proya”) released its financial report for the third quarter of 2025.
According to the data, in the first three quarters, Proya achieved revenue of 7.098 billion yuan, up 1.89 percent year on year, and net profit attributable to shareholders of 1.026 billion yuan, an increase of 2.65 percent. Its gross profit margin reached 73.69 percent. In the third quarter alone, Proya recorded revenue of 1.736 billion yuan, down 11.63 percent year on year, while net profit attributable to shareholders dropped 23.64 percent to 227 million yuan.
As one of China’s leading cosmetics companies, Proya specializes in the research, development, production and sales of beauty products. It operates a multi-brand portfolio including Proya, Timage, Off&Relax and Hapsode, covering skincare, makeup, and hair and body care categories. The company was listed on the main board of the Shanghai Stock Exchange in 2017, earning the title of “China’s First Domestic Beauty Stock.” In 2024, it became the first Chinese beauty brand to join the “10-Billion-Yuan Club.”
In terms of product categories, in the third quarter, Proya sold 21.08 million units of skincare (including cleansing) products, generating 1.316 billion yuan in revenue. Makeup products sold 2.8 million units, contributing 236 million yuan in revenue, while hair and body care products sold 1.86 million units, bringing in 179 million yuan in revenue.
The report also revealed that in the first three quarters, Proya’s R&D expense ratio stood at 2 percent, with total R&D investment reaching 142 million yuan. This shows that Proya continues to increase its investment in research and development in pursuit of differentiated competitive advantages.
In the third quarter, several key initiatives were launched. In July, Proya signed a cooperation agreement with West China Hospital of Sichuan University to jointly focus on mitochondrial anti-aging research, aiming to advance innovation in the beauty industry through cutting-edge medical science. That same month, the company released its first Scalp Microecology White Paper. In September, leveraging its self-developed mitochondrial anti-aging technology, Proya received the “IFSCC 2025 Top 10 Fundamental Research Award.”
Notably, on October 27, Proya’s Hong Kong IPO plan was officially approved at its interim shareholders’ meeting, marking steady progress toward its upcoming listing.
